• AbbVie issued a clarification on the Phase 3 EPCORE DLBCL-1 trial endpoints for epcoritamab in relapsed or refractory DLBCL.
• Overall survival was the sole U.S. primary endpoint. The trial did not show a statistically significant improvement in overall survival.
• The miss on the U.S. primary endpoint raises pressure on epcoritamab’s confirmatory evidence supporting its accelerated approval in DLBCL.
• Additional trial results are slated for submission to a peer-reviewed medical journal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.